Terumo Corporation (TYO:4543)
Japan · Delayed Price · Currency is JPY | Market Cap | 3.54T -7.7% |
| Revenue (ttm) | 1.18T +14.0% |
| Net Income | 164.50B +31.7% |
| EPS | 111.49 +31.9% |
| Shares Out | 1.48B |
| PE Ratio | 21.53 |
| Forward PE | 25.51 |
| Dividend | 36.00 (1.50%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 1,391,400 |
| Open | 2,411.50 |
| Previous Close | 2,399.00 |
| Day's Range | 2,382.50 - 2,423.00 |
| 52-Week Range | 1,900.00 - 2,689.00 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 3,012.31 (+25.51%) |
| Earnings Date | Nov 12, 2026 |
About Terumo
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through four segments: Cardiac and Vascular Company, Medical Care Solutions Company, Blood and Cell Technologies Company, and Terumo Organ Technologies. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents... [Read more]
Financial Performance
In fiscal year 2026, Terumo's revenue was 1.13 trillion, an increase of 9.24% compared to the previous year's 1.04 trillion. Earnings were 135.91 billion, an increase of 16.19%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for 4543 stock is "Buy." The 12-month stock price target is ¥3,012, which is an increase of 25.51% from the latest price.
News
Terumo Transcript: Status update
Integrated engineering, scalable manufacturing, execution capabilities, and AI underpin differentiated products across vascular, imaging, neurovascular, and drug-delivery markets. AI has sharply shortened risk-analysis and toxicology workflows, while 300+ development themes are being prioritized.
Terumo Slides: Status update
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on October 19, 2026.
Terumo (TRUMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Terumo (TRUMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Terumo Slides: Investor presentation
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on October 8, 2026.
Terumo Slides: Acquisition presentation
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Terumo Earnings Call Transcript: Q1 2027
Record-high quarterly revenue and profit were achieved, driven by strong global demand, favorable FX, and significant one-time gains from a U.S. tariff refund and settlement proceeds. Full-year profit guidance was raised, with robust performance across all business segments.
Terumo Quarterly report: Q1 2027
Terumo has published its Q1 2027 quarterly earnings report on August 7, 2026.
Terumo Slides: Q1 2027
Terumo has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 7, 2026.
Terumo Transcript: Investor Day 2026
Core technologies and disciplined investment underpin a scalable growth model, with Africa and organ technologies as key growth engines. New device launches, market expansion, and operational improvements are set to drive revenue and profitability, with further strategic details to be announced in December.
Terumo Slides: FY 2026
Terumo has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Terumo Earnings Call Transcript: Q4 2026
Record revenue and profit achieved for FY 2025, with strong growth across all segments and regions. FY 2026 guidance targets further record highs, driven by organic growth, new product launches, and the integration of OrganOx, despite ongoing tariff and raw material cost pressures.
Terumo Quarterly report: Q4 2026
Terumo has published its Q4 2026 quarterly earnings report on May 15, 2026.
Terumo Slides: Q4 2026
Terumo has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Terumo Earnings Call Transcript: Q3 2026
Record-high revenue and profits were achieved, driven by strong North American demand and effective pricing strategies that offset tariffs and FX headwinds. Acquisitions of Leverkusen Plant and OrganOx contributed to results, and the company remains on track to meet GS 2026 targets.
Terumo Quarterly report: Q3 2026
Terumo has published its Q3 2026 quarterly earnings report on February 13, 2026.
Terumo Slides: Q3 2026
Terumo has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Terumo Transcript: 44th Annual J.P. Morgan Healthcare Conference
Global sales growth is driven by innovation in vascular access, CDMO, and blood technologies, with a focus on margin expansion and strategic M&A. OrganOx acquisition is expected to deliver high double-digit growth and significant market impact, while U.S., Japan, China, and India remain key markets.
Terumo Slides: 44th Annual J.P. Morgan Healthcare Conference
Terumo has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Terumo Earnings Call Transcript: Q2 2026
Record first-half revenue and profits were achieved, driven by strong North American demand, pricing measures, and cost control. Full-year guidance was revised upward, with strategic investments and the Organox acquisition expected to fuel further growth.
Terumo Quarterly report: Q2 2026
Terumo has published its Q2 2026 quarterly earnings report on November 12, 2025.
Terumo Slides: Q2 2026
Terumo has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
OXFORD, England and MADISON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd.
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium
Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with ProSense IceCure joined its exclusive regional distributor, Terumo...
FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.